User login
Objectives: This randomized phase III trial asks whether dose-escalated radiation therapy would be more effective if given concurrently with short-term androgen-deprivation therapy comprising luteinizing-hormone releasing-hormone (LHRH) agonist (leuprolide, goserelin, buserelin, or triptorelin). Overall survival is the primary end point.
Key entry or exclusion criteria: Patients should have histologically confirmed adenocarcinoma of the prostate diagnosed within the past 180 days and be at intermediate-risk for recurrence. Lymph nodes should be clinically negative with no evidence of bone metastases on a bone scan within the past 60 days.
Locations: 263 sites.
Goal: 1,520 patients.
Study sponsor: Radiation Therapy Oncology Group in collaboration with the National Cancer Institute.
Link for more information: clinicaltrials.gov/ct2/show/NCT00936390
NIH clinical trials identifier: NCT00936390
Objectives: This randomized phase III trial asks whether dose-escalated radiation therapy would be more effective if given concurrently with short-term androgen-deprivation therapy comprising luteinizing-hormone releasing-hormone (LHRH) agonist (leuprolide, goserelin, buserelin, or triptorelin). Overall survival is the primary end point.
Key entry or exclusion criteria: Patients should have histologically confirmed adenocarcinoma of the prostate diagnosed within the past 180 days and be at intermediate-risk for recurrence. Lymph nodes should be clinically negative with no evidence of bone metastases on a bone scan within the past 60 days.
Locations: 263 sites.
Goal: 1,520 patients.
Study sponsor: Radiation Therapy Oncology Group in collaboration with the National Cancer Institute.
Link for more information: clinicaltrials.gov/ct2/show/NCT00936390
NIH clinical trials identifier: NCT00936390
Objectives: This randomized phase III trial asks whether dose-escalated radiation therapy would be more effective if given concurrently with short-term androgen-deprivation therapy comprising luteinizing-hormone releasing-hormone (LHRH) agonist (leuprolide, goserelin, buserelin, or triptorelin). Overall survival is the primary end point.
Key entry or exclusion criteria: Patients should have histologically confirmed adenocarcinoma of the prostate diagnosed within the past 180 days and be at intermediate-risk for recurrence. Lymph nodes should be clinically negative with no evidence of bone metastases on a bone scan within the past 60 days.
Locations: 263 sites.
Goal: 1,520 patients.
Study sponsor: Radiation Therapy Oncology Group in collaboration with the National Cancer Institute.
Link for more information: clinicaltrials.gov/ct2/show/NCT00936390
NIH clinical trials identifier: NCT00936390